Physician profile
Donald E Harris
NPI 1508813858
$2,679.58
in general payments reported to CMS, 2019-2025
40 companies · $762 in 2025
The $762 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $81.82 · 2021: $135 · 2022: $69.00 · 2023: $256 · 2024: $638 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,656.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $468.01 | 2023-2025 | |
| Ucb, INC. | $323.44 | 2019-2025 | Briviact, Nayzilam |
| Supernus Pharmaceuticals, INC. | $321.10 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $220.34 | 2019-2025 | |
| Emd Serono, INC. | $183.14 | 2019-2023 | Mavenclad |
| Amgen INC. | $101.87 | 2023-2025 | Uplizna, Aimovig |
| Pfizer INC. | $101.44 | 2019-2024 | |
| Lilly USA, LLC | $97.29 | 2020-2025 | Kisunla, Emgality, Amyvid |
| Amneal Pharmaceuticals LLC | $58.42 | 2023-2025 | Rytary, Crexont |
| Alexion Pharmaceuticals, INC. | $54.24 | 2024-2025 | Ultomiris |
| Inspire Medical Systems, INC. | $48.79 | 2023-2024 | Inspire |
| Acadia Pharmaceuticals INC | $45.91 | 2021-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $42.65 | 2025 | |
| Banner Life Sciences, LLC | $40.07 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.16 | 2025 | Hyqvia |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.